

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/108666 A2

- (51) International Patent Classification⁷: C07D
- (21) International Application Number: PCT/US2004/016036
- (22) International Filing Date: 20 May 2004 (20.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|----------------------------|----|
| 60/474,964 | 2 June 2003 (02.06.2003) | US |
| 60/475,642 | 4 June 2003 (04.06.2003) | US |
| 60/478,648 | 1 August 2003 (01.08.2003) | US |
| 60/566,869 | 30 April 2004 (30.04.2004) | US |








- (71) Applicants and
(72) Inventors: LECANU, Laurent [FR/US]; 8370 Greensboro Drive, Building #4, Apt. 706, McLean, VA 22102 (US). GREESON, Janet [US/US]; 2877 Paradise Road, Suite 801, Las Vegas, NV 89109 (US). PAPADOPOULOS, Vassilios [US/US]; 15417 Peach Leaf Drive, North Potomac, MD 20878 (US).
- (74) Agents: STEFFEY, Charles, E. et al.; Schwegman, Lundberg, Woessner & Kluth, P.A., P.O. Box 2938, Minneapolis, MN 55402 (US).

- (71) Applicants (for all designated States except US): SAMARITAN PHARMACEUTICALS [US/US]; 101 Convention Center Drive, Las Vegas, NV 89109 (US). GEORGETOWN UNIVERSITY [US/US]; Office of Technology Licensing, Box 571408, Washington, DC 20057-1408 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

- (54) Title: NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS



- (57) Abstract: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.

WO 2004/108666 A2